Friday 6 November 2026 Export BBIO’s income statement to Excel — free account

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.

Revenue: +192.6%
EPS: +55.8%
Free cash flow: +60.5%
Total debt: +4.21%

Quarter to September 2026, against a year earlier

73.98 0.29 −0.39%

Follow BBIO

Alert me

Market cap: $14.5B
P/E: 0.0×
Fwd P/E: −27.5×
Dividend yield: —
F-score: 3/9
Altman Z: −3.45
Beneish M: 8.17
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

BridgeBio Pharma, Inc. (BBIO) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, BridgeBio Pharma, Inc. (BBIO) trades at a P/S ratio of 15.5×. Over the past ten years it has ranged from 0.0× (December 2020) to 990× (July 2023); the current reading is higher than 26% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/BBIO/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="BridgeBio Pharma, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/BBIO/metrics/ps-ratio">BridgeBio Pharma, Inc. (BBIO) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	29.2×	26.81%
FY2024	23.0×	(96.75%)
FY2023	708×	5,097.89%
FY2022	13.6×	(60.57%)
FY2021	34.5×	(79.91%)
FY2020	172×	—
FY2019	0.0×	—

Period	P/S ratio	Change
Sep 2026	13.6×	(33.29%)
Jun 2026	20.4×	(18.01%)
Mar 2026	24.9×	(14.52%)
Dec 2025	29.2×	3.59%
23 more quarters	Free account

Against its own ten years

Low 0.0× High 990×

Ten-year median 23.4×

Current reading's percentile 7

Company	P/S ratio
BMRN BioMarin Pharmaceutical Inc. compare	3.0×
JAZZ Jazz Pharmaceuticals PLC compare	3.1×
EXEL Exelixis, Inc. compare	6.8×
HALO Halozyme Therapeutics, Inc. compare	7.8×
TECH Bio-Techne Corp compare	9.3×
ASND Ascendis Pharma A/S compare	13.5×
BBIO BridgeBio Pharma, Inc.	15.5×
KYMR Kymera Therapeutics, Inc. compare	120×
SMMT Summit Therapeutics PLC compare	15,884×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

BridgeBio Pharma, Inc. (BBIO) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on BBIO

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on BBIO

Stockrow Weekly